IL222739A0 - Methods of use soluble cd24 for therapy of rhematoid arthritis - Google Patents

Methods of use soluble cd24 for therapy of rhematoid arthritis

Info

Publication number
IL222739A0
IL222739A0 IL222739A IL22273912A IL222739A0 IL 222739 A0 IL222739 A0 IL 222739A0 IL 222739 A IL222739 A IL 222739A IL 22273912 A IL22273912 A IL 22273912A IL 222739 A0 IL222739 A0 IL 222739A0
Authority
IL
Israel
Prior art keywords
therapy
methods
use soluble
rhematoid arthritis
rhematoid
Prior art date
Application number
IL222739A
Other languages
English (en)
Original Assignee
Oncolmmune Inc
Xincheng Zheng
Wei Wu
Yang Liu
Pan Zheng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolmmune Inc, Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng filed Critical Oncolmmune Inc
Publication of IL222739A0 publication Critical patent/IL222739A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL222739A 2010-04-28 2012-10-28 Methods of use soluble cd24 for therapy of rhematoid arthritis IL222739A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32907810P 2010-04-28 2010-04-28
PCT/US2011/034282 WO2011139820A1 (en) 2010-04-28 2011-04-28 Methods of use of soluble cd24 for therapy of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
IL222739A0 true IL222739A0 (en) 2012-12-31

Family

ID=44903987

Family Applications (1)

Application Number Title Priority Date Filing Date
IL222739A IL222739A0 (en) 2010-04-28 2012-10-28 Methods of use soluble cd24 for therapy of rhematoid arthritis

Country Status (17)

Country Link
US (1) US8808697B2 (cg-RX-API-DMAC7.html)
EP (3) EP2563385B1 (cg-RX-API-DMAC7.html)
JP (5) JP5899206B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130086126A (cg-RX-API-DMAC7.html)
CN (2) CN105381451B (cg-RX-API-DMAC7.html)
AU (1) AU2011248540B2 (cg-RX-API-DMAC7.html)
CA (1) CA2795823C (cg-RX-API-DMAC7.html)
DK (1) DK2563385T3 (cg-RX-API-DMAC7.html)
EA (2) EA027735B1 (cg-RX-API-DMAC7.html)
ES (2) ES2645262T3 (cg-RX-API-DMAC7.html)
IL (1) IL222739A0 (cg-RX-API-DMAC7.html)
NO (1) NO2563385T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ603196A (cg-RX-API-DMAC7.html)
PL (2) PL3260128T3 (cg-RX-API-DMAC7.html)
PT (2) PT3260128T (cg-RX-API-DMAC7.html)
SG (1) SG184907A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011139820A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
CN107531772B (zh) * 2015-05-07 2021-09-21 肿瘤免疫股份有限公司 Cd24用于降低低密度脂蛋白胆固醇水平的用途
SG11201806338SA (en) * 2016-02-02 2018-08-30 Oncoimmune Inc Use of cd24 proteins for treating leptin-deficient conditions
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
KR101789449B1 (ko) * 2016-12-08 2017-10-23 박문수 폐유지를 이용한 지방산 메틸에스테르 제조방법
CN110461353A (zh) * 2017-03-07 2019-11-15 肿瘤免疫股份有限公司 可溶性cd24用于治疗系统性红斑狼疮的使用方法
KR20200034957A (ko) * 2017-05-15 2020-04-01 온코이뮨, 아이앤씨. 신경 보호 및 재수초화를 위한 가용성 cd24의 사용 방법
CN110799206A (zh) * 2017-05-22 2020-02-14 肿瘤免疫股份有限公司 使用可溶性cd24治疗癌症疗法中免疫相关不良事件的方法
AU2019231191A1 (en) * 2018-03-05 2020-09-03 Institute Of Biophysics, Chinese Academy Of Sciences Methods of use of soluble CD24 for treating acquired immune deficiency syndrome (HIV/AIDS)
TWI835794B (zh) * 2018-05-14 2024-03-21 美商昂科Ｃ４公司 抗cd24組合物及其用途
EP3801773A4 (en) * 2018-06-04 2022-03-16 Oncoimmune, Inc. METHOD OF USE OF CD24 FOR PREVENTION AND TREATMENT OF GRAFT VERSUS HOST DISEASE AND MUCOSITIS
EP4017508A1 (en) * 2019-08-23 2022-06-29 Sana Biotechnology, Inc. Cd24 expressing cells and uses thereof
CN112480237B (zh) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 一种融合蛋白及其制备方法和应用
US20250195673A1 (en) * 2020-11-30 2025-06-19 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
EP4408862A4 (en) * 2021-09-28 2025-11-12 Acroimmune Guangzhou Biotech Ltd Fusion proteins including the O71 core peptide and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5798448A (en) * 1994-10-27 1998-08-25 Genentech, Inc. AL-1 neurotrophic factor antibodies
CN101254302B (zh) * 1999-05-07 2011-05-11 杰南技术公司 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病
AU2001259792B2 (en) * 2000-03-29 2005-12-22 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive T cells
US20030106084A1 (en) * 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
HUP0303171A2 (hu) * 2001-02-19 2003-12-29 Merck Patent Gmbh Csökkentett immunogenitású mesterséges fehérjék
US20050214290A1 (en) * 2001-03-29 2005-09-29 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
CA2453406A1 (en) * 2001-07-13 2003-01-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methods for reducing immunogenicity of polypeptides
CA2505601C (en) * 2002-11-15 2014-10-28 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
AU2007242919B8 (en) * 2003-04-09 2011-11-10 F. Hoffmann-La Roche Ag Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
NZ587776A (en) * 2003-04-09 2012-03-30 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody
EP1706507A4 (en) * 2003-11-26 2008-02-20 Univ Ohio State Res Found THE RISK AND PROGRESSION OF MULTIPLE SCLEROSIS PREDICTING POLYMORPHS CD24 GENOTYPES
JP2008507591A (ja) * 2004-05-21 2008-03-13 ゼンコー・インコーポレイテッド 免疫原性が改変されたＣ１ｑファミリーメンバータンパク質
US20060160220A1 (en) * 2004-11-12 2006-07-20 Iogenetics Retroviral vectors with introns

Also Published As

Publication number Publication date
PL3260128T3 (pl) 2021-02-08
CA2795823A1 (en) 2011-11-10
DK2563385T3 (da) 2017-11-06
US8808697B2 (en) 2014-08-19
CN105381451B (zh) 2021-03-09
NZ603196A (en) 2014-07-25
EP2563385B1 (en) 2017-08-02
HK1222554A1 (zh) 2017-07-07
HK1176007A1 (zh) 2013-07-19
WO2011139820A1 (en) 2011-11-10
JP6888221B2 (ja) 2021-06-16
JP2015187162A (ja) 2015-10-29
CN105381451A (zh) 2016-03-09
CA2795823C (en) 2019-06-04
EP3260128A1 (en) 2017-12-27
ES2826445T3 (es) 2021-05-18
JP5899206B2 (ja) 2016-04-06
JP2017057216A (ja) 2017-03-23
PT2563385T (pt) 2017-11-10
EA036805B8 (ru) 2021-02-25
KR20130086126A (ko) 2013-07-31
PL2563385T3 (pl) 2018-04-30
JP2019151655A (ja) 2019-09-12
SG184907A1 (en) 2012-11-29
EP2563385A4 (en) 2013-10-02
CN102869369B (zh) 2016-05-18
EP3845238A1 (en) 2021-07-07
EA036805B1 (ru) 2020-12-23
EA201790538A3 (ru) 2017-11-30
CN102869369A (zh) 2013-01-09
JP2018127493A (ja) 2018-08-16
AU2011248540B2 (en) 2014-11-20
ES2645262T3 (es) 2017-12-04
PT3260128T (pt) 2020-10-22
EA027735B1 (ru) 2017-08-31
EP2563385A1 (en) 2013-03-06
WO2011139820A8 (en) 2013-02-07
JP6062502B2 (ja) 2017-01-18
NO2563385T3 (cg-RX-API-DMAC7.html) 2017-12-30
JP6526872B2 (ja) 2019-06-05
EA201790538A2 (ru) 2017-07-31
EA201290961A1 (ru) 2013-04-30
JP2013527168A (ja) 2013-06-27
US20130136739A1 (en) 2013-05-30
EP3260128B1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
IL222739A0 (en) Methods of use soluble cd24 for therapy of rhematoid arthritis
IL276362A (en) Cancer treatment methods
DK2608777T3 (en) Compositions and Methods for Cardiac Therapy
IL238400A0 (en) Triazolopyrazines as brd4 inhibitors for use in cancer therapy
GB201106527D0 (en) Therapeutic apparatus
AP2013007178A0 (en) BCMA-based stratification and therapy for multiplemyeloma patients
GB201004020D0 (en) New therapeutic use
ZA201304225B (en) Methods of treating cancer
EP2852403A4 (en) METHOD FOR MODIFYING TISSUE
EP2640390A4 (en) METHODS OF TREATING CANCER
IL256026B (en) Treatment methods
SG10201502566SA (en) Use of novel pan-cdk inhibitors for treating tumors
IL222479A (en) Tissue Engineering Methods
SG11201402226PA (en) Therapeutic agent for arthrosis
EP2585115A4 (en) CANCER THERAPY
GB201005394D0 (en) Therapy
GB201016864D0 (en) Therapeutic methods
WO2012037553A9 (en) Use of pkc-iota inhibitors for the treatment of breast cancer
ZA201208905B (en) Cancer therapy method
GB201019034D0 (en) Treatment for tumors
GB201020513D0 (en) Cancer therapy
GB201004674D0 (en) Novel therapy
GB201014042D0 (en) Clinical radiotherapy apparatus
GB201017354D0 (en) Treatment of cancer
GB201004479D0 (en) Therapeutic use of new compounds I

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed